X0306 4 2020-03-13 0 0001717452 Odonate Therapeutics, Inc. ODT 0001759910 Hearne Michael S C/O ODONATE THERAPEUTICS, INC. 4747 EXECUTIVE DRIVE, SUITE 510 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2020-03-13 4 A 0 29 19.59 A 1455 D Common Stock 14075269 I By LP Employee Stock Option (Right to Buy) 23.05 2020-03-13 4 A 0 29 0.00 A 2030-03-13 Common Stock 29 29 D These shares were acquired on 03/13/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in a portion of the shares beneficially held by TCP. The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. /s/ Michael Hearne 2020-03-17